Key result
Ultrasmall superparamagnetic iron oxide (USPIO) contrast agents visualized macrophage infiltrations in a pilot trial of 10 multiple sclerosis patients and other experimental models.
Why the study?
Does USPIO-enhanced MRI improve the visualization of macrophage infiltrations in inflammatory diseases?
Does USPIO-enhanced MRI improve the visualization of macrophage infiltrations in inflammatory diseases?
USPIO-enhanced MRI shows promise as an in vivo surrogate marker for visualizing macrophage-driven inflammation in neurological and vascular diseases.
May support USPIO-MRI as surrogate for macrophage inflammation; leaves open prospective validation before clinical use.
The long blood circulating time and the progressive macrophage uptake in inflammatory tissues of ultrasmall superparamagnetic iron oxide (USPIO) particles are 2 properties of major importance for magnetic resonance imaging (MRI) pathologic tissue characterization. This article reviews the proof of principle of applications such as imaging of carotid atherosclerotic plaque, stroke, brain tumor characterization, or multiple sclerosis. In the human carotid artery, USPIO accumulation in activated macrophages induced a focal drop in signal intensity compared with preinfusion MRI. The USPIO signal alterations observed in ischemic areas of stroke patients is probably related to the visualization of inflammatory macrophage recruitment into human brain infarction since animal experiments in such models demonstrated the internalization of USPIO into the macrophages localized in these areas. In brain tumors, USPIO particles which do not pass the ruptured blood-brain barrier at early times postinjection can be used to assess tumoral microvascular heterogeneity. Twenty-four hours after injection, when the cellular phase of USPIO takes place, the USPIO tumoral contrast enhancement was higher in high-grade than in low-grade tumors. Several experimental studies and a pilot multiple sclerosis clinical trial in 10 patients have shown that USPIO contrast agents can reveal the presence of inflammatory multiple sclerosis lesions. The enhancement with USPIO does not completely overlap with the gadolinium chelate enhancement. While the proof of concept that USPIO can visualize macrophage infiltrations has been confirmed in animals and patients in several applications (carotid atherosclerotic lesions, stroke, brain tumors and multiple sclerosis), larger prospective clinical studies are needed to demonstrate the clinical benefit of using USPIO as an MRI in vivo surrogate marker for brain inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Corot et al. (2004) conducted a review in Central nervous system and carotid atherosclerotic plaque inflammation. Ultrasmall superparamagnetic iron oxide (USPIO) in MRI was evaluated. Ultrasmall superparamagnetic iron oxide (USPIO) contrast agents visualized macrophage infiltrations in a pilot trial of 10 multiple sclerosis patients and other experimental models.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: